Price
CHART BY
Frequently asked questions
What is Alnylam Pharms's market capitalization?
The market capitalization of Alnylam Pharms is $35.39B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Alnylam Pharms's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Alnylam Pharms is 44.66. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Alnylam Pharms?
Alnylam Pharms's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $5.923. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Alnylam Pharms's stock?
Currently, 32 analysts cover Alnylam Pharms's stock, with a consensus target price of $373.05. Analyst ratings provide insights into the stock's expected performance.
What is Alnylam Pharms's revenue over the trailing twelve months?
Over the trailing twelve months, Alnylam Pharms reported a revenue of $4.80B.
What is the EBITDA for Alnylam Pharms?
Alnylam Pharms's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $1.05B. EBITDA measures the company's overall financial performance.
What is the free cash flow of Alnylam Pharms?
Alnylam Pharms has a free cash flow of $793.95M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Alnylam Pharms have, and what sector and industry does it belong to?
Alnylam Pharms employs approximately 2,500 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Alnylam Pharms's shares?
The free float of Alnylam Pharms is 133.37M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $35.39B
- EPS (TTM)
- $5.923
- Free Float
- 133.37M
- P/E ratio (TTM)
- 44.66
- Revenue (TTM)
- $4.80B
- EBITDA (TTM)
- $1.05B
- Free Cashflow (TTM)
- $793.95M
Pricing
- 1D span
- $259.06$267.99
- 52W span
- $197.92$495.31
Analyst Ratings
The price target is $373.05 and the stock is covered by 32 analysts.
Buy
23
Hold
9
Sell
0
Information
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.
- Employees
- 2,500
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- ALNY
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet